Cellectis S.A.
CLLS
Price:
$1.87
Market Cap:
$134.82M
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leuke...[Read more]
Industry
Biotechnology
IPO Date
2015-03-24
Stock Exchange
NASDAQ
Ticker
CLLS
PE Ratio
[-1.61]
ROE
[-75.49%]
Current Ratio
[1.78]
Dividend Yield
[0%]
Enterprise Value
[67.24M]
Dividend History
The ROE as of November 2024 (TTM) for Cellectis S.A. (CLLS) is -75.49%
According to Cellectis S.A.’s latest financial reports and current stock price. The company's current ROE is -75.49%. This represents a change of 281.27% compared to the average of -19.80% of the last 4 quarters.
Cellectis S.A. (CLLS) Historical ROE (quarterly & annually)
How has CLLS ROE performed in the past?
The mean historical ROE of Cellectis S.A. over the last ten years is -38.48%. The current -75.49% ROE has changed 96.16% with respect to the historical average. Over the past ten years (40 quarters), CLLS's ROE was at its highest in in the March 2024 quarter at 6.23%. The ROE was at its lowest in in the December 2023 quarter at -50.61%.
Average
-38.48%
Median
-27.56%
Minimum
-119.32%
Maximum
0.03%
Cellectis S.A. (CLLS) ROE by Quarter and Year
Discovering the peaks and valleys of Cellectis S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 200.52%
Maximum Annual ROE = 0.03%
Minimum Annual Increase = -23851.02%
Minimum Annual ROE = -119.32%
| Year | ROE | Change |
|---|---|---|
| 2023 | -119.32% | 42.63% |
| 2022 | -83.66% | 114.56% |
| 2021 | -38.99% | 48.05% |
| 2020 | -26.33% | -8.49% |
| 2019 | -28.78% | 49.68% |
| 2018 | -19.23% | -48.38% |
| 2017 | -37.25% | 58.60% |
| 2016 | -23.48% | 200.52% |
| 2015 | -7.81% | -23851.02% |
| 2014 | 0.03% | -100.00% |
Cellectis S.A. (CLLS) Average ROE
How has CLLS ROE performed in the past?
The current ROE of Cellectis S.A. (CLLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-80.66%
5-year avg
-59.42%
10-year avg
-38.48%
Cellectis S.A. (CLLS) ROE vs. Peers
How is CLLS’s ROE compared to its peers?
Cellectis S.A.’s ROE is greater than Sigilon Therapeutics, Inc. (-74.73%), greater than DiaMedica Therapeutics Inc. (-43.68%), greater than NeuBase Therapeutics, Inc. (-51.69%), greater than Soleno Therapeutics, Inc. (-61.99%), less than Genfit S.A. (1.77%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than ERYTECH Pharma S.A. (-0.98%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-2516.87%), greater than Innate Pharma S.A. (-84.39%), less than Inhibrx Biosciences, Inc. (1.45%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Passage Bio, Inc. (-72.53%), greater than REGENXBIO Inc. (-70.65%), greater than LianBio (-21.53%), greater than Kezar Life Sciences, Inc. (-59.73%), less than Foghorn Therapeutics Inc. (167.93%), greater than Shattuck Labs, Inc. (-61.92%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Nurix Therapeutics, Inc. (-63.39%),
| Company | ROE | Market cap |
|---|---|---|
| -74.73% | $56.22M | |
| -43.68% | $200.97M | |
| -51.69% | $1.42M | |
| -61.99% | $2.49B | |
| 1.77% | $209.42M | |
| -9.44% | $108.71M | |
| -0.98% | $47.38M | |
| -47.03% | $342.68M | |
| -2516.87% | $29.12M | |
| -84.39% | $131.95M | |
| 1.45% | $203.82M | |
| -184.40% | $37.86M | |
| -36.12% | $5.20B | |
| -72.53% | $31.19M | |
| -70.65% | $475.14M | |
| -21.53% | $34.47M | |
| -59.73% | $54.72M | |
| 167.93% | $435.85M | |
| -61.92% | $47.98M | |
| -62.68% | $521.60M | |
| -24.96% | $2.91B | |
| -63.39% | $1.56B |
Build a custom stock screener for Cellectis S.A. (CLLS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cellectis S.A. (CLLS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cellectis S.A.'s ROE?
How is the ROE calculated for Cellectis S.A. (CLLS)?
What is the highest ROE for Cellectis S.A. (CLLS)?
What is the 3-year average ROE for Cellectis S.A. (CLLS)?
What is the 5-year average ROE for Cellectis S.A. (CLLS)?
How does the current ROE for Cellectis S.A. (CLLS) compare to its historical average?